Quorum Review IRB Announces Updated OnQ Web Portal
Seattle, WA
Quorum Review IRB introduced a new version of the secure OnQ™ portal. The OnQ ™ portal is a powerful information hub providing sponsors, CROs, and investigators immediate access to all Board correspondence and site start-up status information and also allows clients to submit new studies online. The OnQ™ portal now offers sorting and searching capability, making it a valuable tool for clients.
Quorum’s upgraded OnQ™ portal features an enhanced site status report that provides information on the status of site submissions, virtually real-time. In addition, the portal offers access to all Board correspondence, now in a sortable and searchable format for easy retrieval of study documents.
The portal also features a library of helpful resources, including a searchable version of Quorum’s Handbook that allows researchers to find information about Quorum policies and guidelines quickly and easily.
The upgrades to the OnQ™ portal were made with the needs of research organizations in mind, and many were the direct result of feedback that Quorum has received from portal users.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
